Status:
ACTIVE_NOT_RECRUITING
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
Lead Sponsor:
University of California, Los Angeles
Conditions:
Long Covid-19
PASC Post Acute Sequelae of COVID 19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a pilot randomized trial of rTMS for symptoms of fatigue and brain fog, and other neuropsychiatric symptoms of Long-COVID (Post-COVID, post-acute sequelae of COVID-19 infection, PASC). Twenty ...
Eligibility Criteria
Inclusion
- 18+ years of age
- Prior hx of PCR confirmed COVID-19 infection. Determined by the PI or participant's physician.
- Subsequent development of post-acute neuropsychiatric symptoms with fatigue and brain fog as primary outcomes
- USE of Psychotropic medications
- Stable on psychotropic medications for 4+ months
- Confirmed diagnosis of Long COVID
- Subjects are willing and able to adhere to the treatment schedule and required study visits
Exclusion
- Mentally or legally incapacitated or unable to give informed consent
- MOCA \< or = 24
- Infection of poor skin condition over the scalp where the rTMS device will be positioned
- Pregnancy: Female participants will be tested for pregnancy at baseline and agree to use a medically acceptable form of birth control throughout the study, for women younger than 60.
- Lifetime history of diagnosed bipolar disorder; psychosis, such as schizophrenia, schizophreniform, or schizoaffective disorder; intellectual disability (intellectual developmental disorder); organic brain damage; or suicide attempts in the past 24 months.
- Severe MDD with suicidality of Psychosis- excluded
- As-needed use of benzodiazepines and beta-blockers will be permitted but discouraged during assessment days.
- Current abuse or dependence on alcohol or any illicit drug of abuse (disorder in last 6 months). Any recent use of cocaine or opiates will also be exclusionary.
- Participants with asthma or with a history of serious, uncontrolled medical illness or instability (including significant cardio-pulmonary disease, organic brain including significant cardio-pulmonary syndrome, pre-existing dementia, seizure disorder, cerebrovascular disease, and diabetes)
- Taking medications known to lower seizure thresholds (Clozaril/ Wellbutrin)
- Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system.
- Presence of an implanted metallic and magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, infusion pump, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, aneurysm clip, metal prosthesis, or metal aneurysm clips or coils, staples, or stents.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06586398
Start Date
January 1 2025
End Date
December 31 2025
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Semel Institute
Los Angeles, California, United States, 90095